Data from phase III clinical trial of Riavax (GV1001) in metastatic pancreatic cancer presented at conference

RCT (n=148 with high serum eotaxin levels, Korea) reports survival benefit with this immunotherapeutic peptide drug derived from human telomerase, administered in combination with gemcitabine/capecitabine (median overall survival 11.3 vs 7.5 months control; p=0.021).

Biospace Inc.